TTR and amyloidosis: The Phase 3 ENDEAVOUR study was designed to investigate the effect of revusiran, a first-generation GalNAc–siRNA conjugate targeting TTR, in patients with hATTR amyloidosis with cardiomyopathy, a debilitating condition with an average life expectancy of a median 3.4 years from diagnosis.